Skip to main content
Assets
The Procter & Gamble logo
PG.NYSE
The Procter & Gamble
Consumer Staples · Household Products

Multinational consumer goods corporation producing household, health, and personal care products including Tide, Pampers, and Gillette.

HQ: United StatesListed: United States

Historical AI Consensus

Audit every published iPulse AI forecast batch and immutable historical research document for The Procter & Gamble.

Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol
PG.NYSE
Batch
7
Published
September 20, 2026
AI Advisors
14

Historical AI Consensus Investment Thesis

The Procter & Gamble (PG) Stock Forecast and AI Rating

Deep analysis published Original pricing snapshot 12 min read
Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

NEUTRAL

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

NEUTRAL

$148

+0.9%+2.7% incl. dividends
2031

5-Year

NEUTRAL

$180

+22.9%+34.4% incl. dividends

Published batch insight

Consumer Fortress Compounding Defies High Bond Yields and Commodity Headwinds

High consensus confirms that essential daily-use product demand and disciplined share buybacks anchor long-term compounding. While persistent five percent sovereign yields and petrochemical inflation cap multiple expansion, structural supply chain savings and premium tiering ensure resilient free cash generation through economic cycles.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Universal Investor (Polymath) advisor portraitElon Musk (Visionary) advisor portraitSherlock Holmes (Whistleblower) advisor portraitMichael Burry (Vulture) advisor portraitWarren Buffett (Value Purist) advisor portraitRay Dalio (Strategist) advisor portraitSuperintelligence (Anthropologist) advisor portraitMachiavelli (Insider) advisor portraitJ.P. Morgan (Titan) advisor portrait

Universal Investor (Polymath), Elon Musk (Visionary), Sherlock Holmes (Whistleblower), Michael Burry (Vulture), Warren Buffett (Value Purist), Ray Dalio (Strategist), Superintelligence (Anthropologist), Machiavelli (Insider), J.P. Morgan (Titan). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models
Gemini AI model logoGeminiClaude AI model logoClaudeChatGPT AI model logoChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in The Procter & Gamble at the forecast anchor (2026-09-18): $13,437 in five years versus $13,892 for S&P 500 benchmark.

Five-year synthesized consensus forecast for The Procter & GambleThe diagram shows the synthesized consensus value path for The Procter & Gamble, forecast milestones, and a comparison with S&P 500 benchmark. including estimated net dividends of 1.8% per year.$10,000$12,500$15,000$13,437 (+34.4%)$13,892 (+38.9%)Anchor2026-09-182027(1Y)2028(2Y)2029(3Y)2030(4Y)2031(5Y)
The Procter & Gamble · Synthesized ConsensusS&P 500 benchmark

* Return is calculated incl. 1.8% net dividend yield for The Procter & Gamble.

Figure: Five-year synthesized consensus value path for The Procter & Gamble compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each step

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 146.39 USD1-year price return: +0.90%5-year price return: +22.91%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
QuarterTarget (USD)Quarter returnTotal returnForecast rationale
Q4 2026144.74-1.12%-1.12%Elevated petrochemical input costs and five percent Treasury yields compress valuation multiples. First-quarter fiscal 2027 results reveal muted volume growth, keeping prices subdued despite safe-haven equity inflows.
Q1 2027143.84-0.63%-1.74%Winter retail channel negotiations demonstrate consumer resistance to price hikes across domestic aisles. Input cost pressures squeeze reported margins, causing modest equity softening as investors seek higher-yielding cash alternatives.
Q2 2027145.86+1.40%-0.36%The annual dividend increase announcement reinforces investor confidence in defensive cash generation. Initial restructuring efficiencies and steady share buybacks counteract commodity inflation, enabling a modest equity rebound.
Q3 2027147.71+1.27%+0.90%Fiscal 2027 full-year disclosures confirm core earnings meet revised guidance. Completion of organizational restructuring milestones removes known headwinds, allowing institutional allocators to stabilize baseline valuation multiples.
Q4 2027149.77+1.39%+2.31%Holiday replenishment across essential personal health and fabric care categories delivers solid revenue conversion. Moderating energy logistics friction improves quarterly operating leverage, driving a modest per-share valuation advance.
Q1 2028151.29+1.02%+3.35%Supply chain modernization generates verifiable overhead savings, offsetting sticky retail labor and freight expenses. Modest private-label encroachment caps broader multiple expansion, keeping price appreciation measured and disciplined.
Q2 2028153.55+1.49%+4.89%Confirmation of another consecutive annual dividend progression underscores pristine balance sheet stewardship. Accelerating free cash flow conversion and programmatic share repurchases support a decisive two percent quarterly price gain.
Q3 2028155.53+1.29%+6.24%Audited fiscal 2028 figures reveal balanced organic revenue growth across core segments. Restructuring savings annualize cleanly into operating income, reinforcing institutional demand for resilient, low-beta defensive cash flow.
Q4 2028158.12+1.66%+8.01%Stabilizing commodity markets reduce packaging resin and surfactant procurement costs. Favorable sales mix toward premium grooming and oral care tiers expands quarterly gross margins, supporting positive equity performance.
Q1 2029160.03+1.21%+9.32%Monetary policy normalization slightly compresses benchmark sovereign yields, enhancing the relative attractiveness of defensive dividend distributions. Stable household replenishment demand preserves market share across Tier-1 retail distributors.
Q2 2029161.79+1.10%+10.52%Digital manufacturing and automated fulfillment initiatives achieve targeted scale, driving unit conversion costs lower. Expanded operating margins translate directly into robust per-share earnings growth, generating solid equity appreciation.
Q3 2029163.85+1.28%+11.93%Full-year fiscal 2029 reporting exhibits resilient three percent organic top-line expansion. Systematic float reduction via continuous open-market repurchases buffers per-share intrinsic value against residual foreign exchange friction.
Q4 2029166.64+1.70%+13.83%Emerging market volume expansion across Latin America and South Asia offsets mature market plateauing. Strong winter health and home hygiene consumption provides steady quarterly revenue, lifting equity valuations.
Q1 2030168.00+0.82%+14.77%Valuation multiples consolidate near twenty times forward earnings as interest rates settle into mid-cycle norms. Disciplined working capital execution protects cash flow, keeping price movement closely tied to earnings.
Q2 2030170.78+1.65%+16.66%Fiscal 2030 closure demonstrates record operating cash flows approaching twenty billion dollars. Management's regular dividend increase and accretive share retirements reward patient shareholders with steady, compounding capital appreciation.
Q3 2030172.43+0.96%+17.79%Packaging sustainability adaptations are smoothly absorbed without denting consolidated gross margins. Defensive asset allocators maintain stable positioning, balancing mature category volume growth against dependable shareholder cash distributions.
Q4 2030174.50+1.20%+19.20%Year-end retail volume velocity remains durable across essential hygiene and daily care franchises. Strong cash conversion easily covers capital expenditures and debt service, driving modest period-over-period price gains.
Q1 2031175.92+0.82%+20.17%Predictable household replenishment demand insulates corporate revenues from broader macroeconomic deceleration. The equity consolidates around fair value as balanced operating performance neutralizes modest competitive promotional intensity.
Q2 2031177.92+1.13%+21.54%A milestone seventy-fifth consecutive annual dividend raise affirms elite income credentials. Continuous enterprise productivity programs keep operating margins above twenty-three percent, supporting an incremental quarterly price advance.
Q3 2031179.92+1.12%+22.91%Concluding the five-year horizon, normalized per-share earnings reach target bands near nine dollars. Durable balance sheet liquidity and unmatched retail shelf dominance secure steady, compounding shareholder value.

The base-case economic thesis identifies a mature consumer fast-moving goods leader traversing a structural transition from price-led expansion to cost-led compounding. With fiscal 2026 organic sales growth entirely price-driven and unit volumes flat, operating leverage has temporarily reversed under elevated petrochemical feedstocks and shipping overhead. Nevertheless, unmatched retail shelf hegemony and non-discretionary consumer replenishment cycles protect gross margins above fifty percent. Valuation multiples face natural gravitational drag from five percent sovereign discount rates, precluding multiple expansion beyond historical bands. Compounding will therefore be generated fundamentally through systematic owner earnings: fifteen billion dollars in recurring free cash flow, one point five billion dollars in annual productivity savings, and steady share count retirement of over one percent annually.

Key insights

  • Sustained five percent risk-free yields create an inverted equity risk premium, permanently capping defensive valuation multiples near twenty times forward earnings.
  • Supply Chain 3.0 restructuring offsets input inflation, but required marketing reinvestment prevents gross savings from fully translating into operating profit.
  • Negative working capital velocity provides immense balance sheet resilience, funding unbroken dividend progression without requiring external debt capital.

Deep Dive

Prevailing market sentiment treats the asset as an untouchable bond-proxy haven whose brand pricing power effortlessly shields investors from inflation. Sell-side research models steady three percent organic expansion and unbroken dividend progression, pricing the shares at twenty-one times forward earnings. However, the crowd overlooks that five percent risk-free yields make defensive dividend yields less competitive while price-led volume growth faces consumer exhaustion.